Secondary neurological and functional outcomes
| Outcome | 4–8 weeks post discharge | 12 months post randomisation | ||
| IVIG (n=10) | Placebo (n=8) | IVIG (n=10) | Placebo (n=8) | |
| LOS | ||||
| Severe sequelae | 2 (20%) | 2 (25%) | 2 (20%) | 2 (25%) |
| Moderate sequelae | 2 (20%) | 3 (38%) | 1 (10%) | 1 (13%) |
| Minor sequelae | 1 (10%) | 0 (0%) | 1 (10%) | 1 (3%) |
| Full recovery | 3 (30%) | 2 (25%) | 4 (40%) | 2 (25%) |
| Missing data due to withdrawal or loss to follow-up of participant | 1 (10%) | 1 (13%) | 2 (20%) | 2 (25%) |
| Missing data—assessment not performed | 1 (10%) | 0 (0%) | 0 (%) | 0 (%) |
| PedsQL | ||||
| Mean (SD) | 77.9 (11.1) | 56.5 (7.8) | 79.9 (21.6) | 63.7 (30.1) |
| Missing data due to withdrawal or loss to follow-up of participant | 1 (10%) | 1 (13%) | 2 (20%) | 2 (25%) |
| Missing data—assessment not performed | 4 (40%) | 5 (63%) | 2 (20%) | 4 (50%) |
| SDQ | ||||
| Close to average | 4 (40%) | 1 (13%) | 4 (40%) | 1 (13%) |
| Slightly raised | 1 (10%) | 0 (0%) | 1 (10%) | 0 (0%) |
| Very high | 0 (0%) | 1 (13%) | 1 (10%) | 1 (13%) |
| Missing data due to withdrawal or loss to follow-up of participant | 1 (10%) | 1 (13%) | 2 (20%) | 2 (25%) |
| Missing data—assessment not performed | 4 (40%) | 5 (63%) | 2 (20%) | 4 (50%) |
| ABAS | ||||
| Very superior | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) |
| Superior | 1 (10%) | 0 (0%) | 1 (10%) | 0 (0%) |
| Above average | 1 (10%) | 0 (0%) | 1 (10%) | 0 (0%) |
| Average | 2 (20%) | 1 (13%) | 0 (0%) | 1 (13%) |
| Below average | 0 (0%) | 1 (13%) | 1 (10%) | 0 (0%) |
| Borderline | 1 (10%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Extremely low | 1 (10%) | 0 (0%) | 1 (10%) | 1 (13%) |
| Missing data due to withdrawal or loss to follow-up of participant | 1 (10%) | 1 (13%) | 2 (20%) | 2 (25%) |
| Missing data—assessment not performed | 3 (30%) | 5 (63%) | 3 (30%) | 4 (50%) |
| GMFCS* | ||||
| Mild | 5 (50%) | 2 (25%) | 6 (60%) | 1 (13%) |
| Severe | 0 (0%) | 1 (13%) | ||
| Missing data due to withdrawal or loss to follow-up of participant | 1 (10%) | 1 (13%) | 2 (20%) | 2 (25%) |
| Missing data—assessment not performed | 4 (40%) | 5 (63%) | 2 (20%) | 4 (50%) |
| GOSE-Peds at 6 months post randomisation | ||
| IVIG (n=10) | Placebo (n=8) | |
| Upper good recovery | 4 (40%) | 4 (50%) |
| Upper moderate disability | 1 (10%) | 1 (13%) |
| Upper severe disability | 0 (0%) | 1 (13%) |
| Lower severe disability | 3 (30%) | 1 (13%) |
| Missing data due to withdrawal or loss to follow-up of participant | 2 (20%) | 1 (13%) |
| Missing data—assessment not performed | 0 (0%) | 0 (0%) |
ABAS, Adaptive Behavior Assessment System; GMFCS, Gross Motor and Function Classification System; GOSE-Peds, Paediatric Glasgow Outcome Score Extended; LOS, Liverpool Outcome Score; SDQ, Strengths and Difficulty Questionnaire.